Overview

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Status:
Recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

Diwakar Davar

Collaborator:

Tesaro, Inc.